Answers are grounded in this paper and cite their sources.
// Anna Passarelli 1 , Francesco Mannavola 1 , Luigia Stefania Stucci 1 , Marco Tucci 1 and Francesco Silvestris 1 1 Department of Biomedical Sciences and Human Oncology, University of Bari ‘Aldo Moro’, Bari, Italy Correspondence to: Anna Passarelli, email: passarellian@libero.it Keywords: melanoma; immune system; immunogenicity; immunoediting; immune escape Received: May 26, 2017 Accepted: September 21, 2017 Published: October 31, 2017 ABSTRACT Melanoma is one of the most immunogenic tumors and its relationship with host immune system is currently under investigation. Many immunomodulatory mechanisms, favoring melanomagenesis and progression, have been described to interfere with the disablement of melanoma recognition and attack by immune cells resulting in immune resistance and immunosuppression. This knowledge produced therapeutic advantages, such as immunotherapy, aiming to overcome the immune evasion. Here, we review the current advances in cancer immunoediting and focus on melanoma immunology, which involves a dynamic interplay between melanoma and immune system, as well as on effects of “targeted therapies” on tumor microenvironment for combination strategies.
No takes yet. Share an insight, caveat, or question.
Passarelli et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: